These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 7171656

  • 1. Fluphenazine blood levels and clinical response.
    Harris PQ, Friedman MJ, Cohen BM, Cooper TB.
    Biol Psychiatry; 1982 Oct; 17(10):1123-30. PubMed ID: 7171656
    [Abstract] [Full Text] [Related]

  • 2. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [Abstract] [Full Text] [Related]

  • 3. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA, Silver MA.
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [Abstract] [Full Text] [Related]

  • 4. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
    Cohen BM, Waternaux C, Chouinard G, Sommer BR, Jones B.
    J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
    [Abstract] [Full Text] [Related]

  • 5. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G, Coyle J, Tune L.
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [Abstract] [Full Text] [Related]

  • 6. Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
    Heresco-Levy U, Greenberg D, Lerer B, Javitt DC, Brown WA.
    Isr J Psychiatry Relat Sci; 1997 May; 34(4):281-9. PubMed ID: 9409085
    [Abstract] [Full Text] [Related]

  • 7. Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine.
    Marder SR, Van Putten T, Aravagiri M, Hubbard JW, Hawes EM, McKay G, Midha KK.
    Psychopharmacol Bull; 1989 May; 25(3):479-82. PubMed ID: 2626520
    [Abstract] [Full Text] [Related]

  • 8. Serum haloperidol and neuroleptic receptor levels in chronic psychosis.
    Cannon DJ, McMillan DE, Newton JE, Fody EP, Metzer WS, Claybrook M, Couch L, Paige SR.
    Ann Clin Lab Sci; 1988 May; 18(5):378-83. PubMed ID: 3178137
    [Abstract] [Full Text] [Related]

  • 9. Fluphenazine plasma levels and clinical response.
    Marder SR, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, McKay G, Mintz J, Midha KK.
    Psychopharmacol Bull; 1990 May; 26(2):256-9. PubMed ID: 2236467
    [Abstract] [Full Text] [Related]

  • 10. Fluphenazine plasma levels and clinical response.
    Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL.
    J Clin Psychiatry; 1984 Sep; 45(9):370-3. PubMed ID: 6381472
    [Abstract] [Full Text] [Related]

  • 11. [Social integration of long-term paraphrenic patients with low-dose depot neuroleptic medication].
    Lesch OM, Dietzel-Rogan M, Musalek M, Rajna P, Rustembegovich A, Schjerve M, Walter H.
    Psychiatr Prax; 1985 Mar; 12(2):63-8. PubMed ID: 3887443
    [Abstract] [Full Text] [Related]

  • 12. Plasma fluphenazine levels measured by high-performance liquid chromatography in patients treated with depot injections.
    Jouen F, Verité P, André D, Colonna L, Boucly P.
    Arzneimittelforschung; 1993 May; 43(5):509-11. PubMed ID: 8328993
    [Abstract] [Full Text] [Related]

  • 13. Low neuroleptic serum levels in patients receiving fluphenazine decanoate.
    Tune LE, Creese I, Coyle JT, Pearlson G, Snyder SH.
    Am J Psychiatry; 1980 Jan; 137(1):80-2. PubMed ID: 6101523
    [Abstract] [Full Text] [Related]

  • 14. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
    Mamo DC, Sweet RA, Chengappa KN, Reddy RR, Jeste DV.
    Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
    [Abstract] [Full Text] [Related]

  • 15. Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients.
    Van Putten T, Aravagiri M, Marder SR, Wirshing WC, Mintz J, Chabert N.
    Psychopharmacol Bull; 1991 Nov; 27(2):91-6. PubMed ID: 1924666
    [Abstract] [Full Text] [Related]

  • 16. Neuroleptic serum levels measured by radioreceptor assay in patients receiving intramuscular depot neuroleptics. Some preliminary findings.
    Turbott J, Villiger J, Hunter L.
    Br J Psychiatry; 1985 Apr; 146():439-42. PubMed ID: 4016448
    [Abstract] [Full Text] [Related]

  • 17. Correction of serum neuroleptic activity for blood-to-brain distribution: a method that may render radioreceptor assay results comparable between neuroleptics.
    Young AS, Faraone SV, Brown WA.
    J Clin Psychopharmacol; 1989 Oct; 9(5):361-3. PubMed ID: 2571620
    [Abstract] [Full Text] [Related]

  • 18. Depot neuroleptic medication and serum levels by radioreceptor assay: prolactin concentration, electrocardiogram abnormalities and six-month outcome.
    Turbott J, Villiger J, Hunter L.
    Aust N Z J Psychiatry; 1987 Sep; 21(3):327-38. PubMed ID: 3435373
    [Abstract] [Full Text] [Related]

  • 19. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches.
    Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR.
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):50-9. PubMed ID: 6143748
    [Abstract] [Full Text] [Related]

  • 20. Persistence of fluphenazine in plasma after decanoate withdrawal.
    Gitlin MJ, Midha KK, Fogelson D, Nuechterlein K.
    J Clin Psychopharmacol; 1988 Feb; 8(1):53-6. PubMed ID: 3351000
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.